EU regulators recommend approval of Merck's drug Welireg for certain patients with VHL disease or advanced kidney cancer.

Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock ...

Shares of Merck & Co. Inc. MRK inched 0.74% higher to $102.00 Friday, on what proved to be an all-around mixed trading ...

We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a ...

Merck & Co. Inc. closed $33.63 below its 52-week high ($134.63), which the company achieved on June 25th.

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

We recently published a list of 11 Best Beginner Stocks To Invest In Now. In this article, we are going to take a look at ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...

(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Friday that its WELIREG (belzutifan) has received positive opinion from the European Medicines Agency's Committee for Medicinal Products for ...

In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may ...

Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate, trumpeting a 100% complete response rate but ...

在分析师评论方面，Jefferies将公司股票目标价上调至148美元，这是在默沙东战略性地从LaNova获得临床前PD1xVEGF疗法许可之后。然而，BMO Capital Markets因担心Gardasil疫苗在中国的表现而下调了对默沙东的展望，降低了目标价。